Anemia Research Today is a free monthly online journal that collates and summarizes the latest research about Anemia, including details on symptoms, diagnosis, diet, treatment, causes. | ||||||||
|
Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy: results of the NeoPrevent study.de Castro J, Ordóñez A, Isla D, Sánchez A, Arrivi A, Manzano JL, Barón MG Servicio de Oncología Médica, Hospital Universitario La Paz (Madrid), Paseo de la Castellana, 261, 28046, Madrid, Spain. BACKGROUND: Anaemia is common during platinum-based chemotherapy. This study aimed to evaluate the efficacy and safety of epoetin beta in the prevention of severe anaemia in patients with solid tumours receiving concomitant platinum therapy. PATIENTS AND METHODS: In this open-label, single-arm study, patients (n = 255) with solid tumours and haemoglobin (Hb) levels </= 13 g/dl (men) or </= 12 g/dl (women) received epoetin beta 450 IU/kg ( approximately 30,000 IU) weekly until 4 weeks after their last platinum-based chemotherapy cycle. RESULTS: An anaemia prevention response [defined as patients with a Hb response (increase in Hb level > 1 g/dl from baseline) plus patients whose Hb levels remained +/- 1 g/dl of baseline throughout the study] was observed in 234 patients (92%). Response to epoetin beta was rapid. Of the 159 patients achieving a Hb response, 139 (87%) had Hb levels > 1 g/dl of baseline within 4 weeks of treatment initiation. Mean Hb levels had improved from 10.8 +/- 1.0 g/dl at baseline to 12.2 +/- 1.8 g/dl by the final visit. Quality of life measured by linear analogue scale assessment significantly (P < 0.01) improved in patients achieving a Hb response (n = 159). CONCLUSIONS: Epoetin beta effectively prevents anaemia in most patients with solid tumours receiving concurrent platinum-based chemotherapy. Published 22 November 2006 in Cancer Chemother Pharmacol, 59(1): 35-42.
© 2004-2008 Anemia Research Today. All Rights Reserved. |
| ||||||
